BibTex RIS Cite

Treatment Strategies of Pulmonary Arterial Hypertension Associated with Congenital Heart Defects with Shunt: A Group of Important Intensive Care Patient in Cardiology and Cardiovascular Surgery

Year 2013, Volume: 16 Issue: 3, 173 - 176, 01.03.2012
https://doi.org/10.5578/kkd.6837

Abstract

References

  • D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hyper- tension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
  • Korurek M, Yildiz M, Yüksel A, Şahin A. Simulation of Eisenmen- ger syndrome with ventricular septal defect using equivalent elect- ronic system. Cardiol Young 2012;22:301-6.
  • Yıldız M, Yüksel A, Korürek M, Aykan AÇ, Şahin Yıldız B, Şa- hin A, et al. Classifi cation of Aatrial septal defect and ventricular septal defect with documented hemodynamic parameters via vardiac catheterization by genetic algorithms and multi-layered artifi cial neural network. Kosuyolu Kalp Derg 2012;15:45-50.
  • Engelfriet PM, Duffels MGJ, Moller T, Boersma E, Tijssen JGP, Thaulow E, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult conge- nital heart disease. Heart 2007;93:682-7.
  • Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, et al. Eisenmenger syndrome. Factors relating to dete- rioration and death. Eur Heart J 1998;19:1845-55.
  • Beghetti M, Galie N. Eisenmenger syndrome: a clinical perspecti- ve in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009;53:733-40.
  • Broberg CS, Ujita M, Prasad S, Li W, Rubens M, Bax BE, et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is as- sociated with biventricular dysfunction and decreased pulmonary fl ow velocity. J Am Coll Cardiol 2007;50:634-42.
  • Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulati- on 2013;127:1128-38.
  • Xiong CM, Lu XL, Shan GL, Wu BX, Zhu XY, Wu GH, et al. Oral sil- denafi l therapy for Chinese patients with pulmonary arterial hyper- tension: a multicenter study. J Clin Pharmacol 2012;52:425-31.
  • Gatzoulis MA, Alonso-Gonzalez R, Beghetti M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 2009;18:154-61.
  • Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, La- uer A, et al.; Bosentan Randomized Trial of Endothelin Antago- nist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48- 54.
  • Cacoub P, Dorent R, Nataf P, Carayon A. Endothelin-1 in pulmo- nary hypertension. N Engl J Med 1993;329:1967-8.
  • Gatzoulis MA, Beghetti M, Galiè N, Granton J, Berger RM, Lauer A, et al.; BREATHE-5 Investigators. Longer-term bosentan the- rapy improves functional capacity in Eisenmenger syndrome: re- sults of the BREATHE-5 open-label extension study. Int J Cardiol 2008;127:27-32.
  • Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenz- weig EB. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol 2011;107:1381-5.
  • Prasad S, Wilkinson J, Gatzoulis MA. Sildenafi l in primary pulmo- nary hypertension. N Engl J Med 2000;343:1342.
  • Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Benefi cial effect of oral sildenafi l therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-la- bel, pilot study. Circulation 2005;111:3274-80.
  • Chau EM, Fan KY, Chow WH. Effects of chronic sildenafi l in pa- tients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007;120:301-5.
  • Mukhopadhyay S, Sharma M, Ramakrishnan S, Yusuf J, Gupta MD, Bhamri N, et al. Phosphodiesterase- 5 inhibitor in Eisen- menger syndrome: a preliminary observational study. Circulation 2006;114:1807-10.
  • Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-65.
  • Thomas IC, Glassner-Kolmin C, Gomberg-Maitland M. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease. Int J Car- diol 2013;168:4117-21.
  • D’Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, et al. Bosentan-sildenafi l association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisen- menger physiology. Int J Cardiol 2012;155:378-82.
  • Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenafi l in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010;31:1124-31.
  • Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, et al. Improved survival among patients with Eisenmen- ger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010;121:20-5.
  • Gatzoulis MA, Alonso-Gonzalez R, Beghetti M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 2009;18:154-61.

Doğumsal Kardiyak Şantlarla Bağlantılı Pulmoner Arteriyel Hipertansiyonda Tedavi Yaklaşımları: Kardiyoloji ve Kalp-Damar Cerrahisinde Önemli Bir Yoğun Bakım Hasta Grubu

Year 2013, Volume: 16 Issue: 3, 173 - 176, 01.03.2012
https://doi.org/10.5578/kkd.6837

Abstract

hipertansiyonda kombinasyon tedavisiyle ilgili yapılan ça- lışmalardan elde edilen veriler çelişkilidir. Bazı çalışmalar- da bosentan tedavisine sildenafi l eklenmesi hemodinamik özellikleri ve egzersiz kapasitesini artırırken; bazı çalışma- larda kombinasyon tedavisi etkisiz bulunmuştur(23). Fakat yine de doğumsal kalp hastalığıyla ilişkili pulmoner arte- riyel hipertansiyon hastalarının, pulmoner arteriyel hiper- tansiyon spesifi k tedaviden fayda gördüğü gösterilmiştir. Ortalama dört yıl takip edilen toplam 229 Eisenmenger sendromlu hastada yapılan retrospektif bir çalışmada pul- moner arteriyel hipertansiyon spesifi k tedavi gören grupta, tedavi almayan gruba göre daha düşük ölüm oranı saptan- mıştır(24)

References

  • D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hyper- tension. Results from a national prospective registry. Ann Intern Med 1991;115:343-9.
  • Korurek M, Yildiz M, Yüksel A, Şahin A. Simulation of Eisenmen- ger syndrome with ventricular septal defect using equivalent elect- ronic system. Cardiol Young 2012;22:301-6.
  • Yıldız M, Yüksel A, Korürek M, Aykan AÇ, Şahin Yıldız B, Şa- hin A, et al. Classifi cation of Aatrial septal defect and ventricular septal defect with documented hemodynamic parameters via vardiac catheterization by genetic algorithms and multi-layered artifi cial neural network. Kosuyolu Kalp Derg 2012;15:45-50.
  • Engelfriet PM, Duffels MGJ, Moller T, Boersma E, Tijssen JGP, Thaulow E, et al. Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult conge- nital heart disease. Heart 2007;93:682-7.
  • Daliento L, Somerville J, Presbitero P, Menti L, Brach-Prever S, Rizzoli G, et al. Eisenmenger syndrome. Factors relating to dete- rioration and death. Eur Heart J 1998;19:1845-55.
  • Beghetti M, Galie N. Eisenmenger syndrome: a clinical perspecti- ve in a new therapeutic era of pulmonary arterial hypertension. J Am Coll Cardiol 2009;53:733-40.
  • Broberg CS, Ujita M, Prasad S, Li W, Rubens M, Bax BE, et al. Pulmonary arterial thrombosis in Eisenmenger syndrome is as- sociated with biventricular dysfunction and decreased pulmonary fl ow velocity. J Am Coll Cardiol 2007;50:634-42.
  • Hoeper MM, Barst RJ, Bourge RC, Feldman J, Frost AE, Galié N, et al. Imatinib mesylate as add-on therapy for pulmonary arterial hypertension: results of the randomized IMPRES study. Circulati- on 2013;127:1128-38.
  • Xiong CM, Lu XL, Shan GL, Wu BX, Zhu XY, Wu GH, et al. Oral sil- denafi l therapy for Chinese patients with pulmonary arterial hyper- tension: a multicenter study. J Clin Pharmacol 2012;52:425-31.
  • Gatzoulis MA, Alonso-Gonzalez R, Beghetti M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 2009;18:154-61.
  • Galiè N, Beghetti M, Gatzoulis MA, Granton J, Berger RM, La- uer A, et al.; Bosentan Randomized Trial of Endothelin Antago- nist Therapy-5 (BREATHE-5) Investigators. Bosentan therapy in patients with Eisenmenger syndrome: a multicenter, double-blind, randomized, placebo-controlled study. Circulation 2006;114:48- 54.
  • Cacoub P, Dorent R, Nataf P, Carayon A. Endothelin-1 in pulmo- nary hypertension. N Engl J Med 1993;329:1967-8.
  • Gatzoulis MA, Beghetti M, Galiè N, Granton J, Berger RM, Lauer A, et al.; BREATHE-5 Investigators. Longer-term bosentan the- rapy improves functional capacity in Eisenmenger syndrome: re- sults of the BREATHE-5 open-label extension study. Int J Cardiol 2008;127:27-32.
  • Zuckerman WA, Leaderer D, Rowan CA, Mituniewicz JD, Rosenz- weig EB. Ambrisentan for pulmonary arterial hypertension due to congenital heart disease. Am J Cardiol 2011;107:1381-5.
  • Prasad S, Wilkinson J, Gatzoulis MA. Sildenafi l in primary pulmo- nary hypertension. N Engl J Med 2000;343:1342.
  • Humpl T, Reyes JT, Holtby H, Stephens D, Adatia I. Benefi cial effect of oral sildenafi l therapy on childhood pulmonary arterial hypertension: twelve-month clinical trial of a single-drug, open-la- bel, pilot study. Circulation 2005;111:3274-80.
  • Chau EM, Fan KY, Chow WH. Effects of chronic sildenafi l in pa- tients with Eisenmenger syndrome versus idiopathic pulmonary arterial hypertension. Int J Cardiol 2007;120:301-5.
  • Mukhopadhyay S, Sharma M, Ramakrishnan S, Yusuf J, Gupta MD, Bhamri N, et al. Phosphodiesterase- 5 inhibitor in Eisen- menger syndrome: a preliminary observational study. Circulation 2006;114:1807-10.
  • Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99:1858-65.
  • Thomas IC, Glassner-Kolmin C, Gomberg-Maitland M. Long-term effects of continuous prostacyclin therapy in adults with pulmonary hypertension associated with congenital heart disease. Int J Car- diol 2013;168:4117-21.
  • D’Alto M, Romeo E, Argiento P, Sarubbi B, Santoro G, Grimaldi N, et al. Bosentan-sildenafi l association in patients with congenital heart disease-related pulmonary arterial hypertension and Eisen- menger physiology. Int J Cardiol 2012;155:378-82.
  • Iversen K, Jensen AS, Jensen TV, Vejlstrup NG, Sondergaard L. Combination therapy with bosentan and sildenafi l in Eisenmenger syndrome: a randomized, placebo-controlled, double-blinded trial. Eur Heart J 2010;31:1124-31.
  • Dimopoulos K, Inuzuka R, Goletto S, Giannakoulas G, Swan L, Wort SJ, et al. Improved survival among patients with Eisenmen- ger syndrome receiving advanced therapy for pulmonary arterial hypertension. Circulation 2010;121:20-5.
  • Gatzoulis MA, Alonso-Gonzalez R, Beghetti M. Pulmonary arterial hypertension in paediatric and adult patients with congenital heart disease. Eur Respir Rev 2009;18:154-61.
There are 24 citations in total.

Details

Primary Language Turkish
Journal Section Articles
Authors

Mustafa Yıldız This is me

Hasan Sunar This is me

Ali Metin Esen This is me

Publication Date March 1, 2012
Published in Issue Year 2013 Volume: 16 Issue: 3

Cite

APA Yıldız, M. ., Sunar, H. ., & Esen, A. M. . (2012). Doğumsal Kardiyak Şantlarla Bağlantılı Pulmoner Arteriyel Hipertansiyonda Tedavi Yaklaşımları: Kardiyoloji ve Kalp-Damar Cerrahisinde Önemli Bir Yoğun Bakım Hasta Grubu. Koşuyolu Kalp Dergisi, 16(3), 173-176. https://doi.org/10.5578/kkd.6837
AMA Yıldız M, Sunar H, Esen AM. Doğumsal Kardiyak Şantlarla Bağlantılı Pulmoner Arteriyel Hipertansiyonda Tedavi Yaklaşımları: Kardiyoloji ve Kalp-Damar Cerrahisinde Önemli Bir Yoğun Bakım Hasta Grubu. Koşuyolu Kalp Dergisi. March 2012;16(3):173-176. doi:10.5578/kkd.6837
Chicago Yıldız, Mustafa, Hasan Sunar, and Ali Metin Esen. “Doğumsal Kardiyak Şantlarla Bağlantılı Pulmoner Arteriyel Hipertansiyonda Tedavi Yaklaşımları: Kardiyoloji Ve Kalp-Damar Cerrahisinde Önemli Bir Yoğun Bakım Hasta Grubu”. Koşuyolu Kalp Dergisi 16, no. 3 (March 2012): 173-76. https://doi.org/10.5578/kkd.6837.
EndNote Yıldız M, Sunar H, Esen AM (March 1, 2012) Doğumsal Kardiyak Şantlarla Bağlantılı Pulmoner Arteriyel Hipertansiyonda Tedavi Yaklaşımları: Kardiyoloji ve Kalp-Damar Cerrahisinde Önemli Bir Yoğun Bakım Hasta Grubu. Koşuyolu Kalp Dergisi 16 3 173–176.
IEEE M. . Yıldız, H. . Sunar, and A. M. . Esen, “Doğumsal Kardiyak Şantlarla Bağlantılı Pulmoner Arteriyel Hipertansiyonda Tedavi Yaklaşımları: Kardiyoloji ve Kalp-Damar Cerrahisinde Önemli Bir Yoğun Bakım Hasta Grubu”, Koşuyolu Kalp Dergisi, vol. 16, no. 3, pp. 173–176, 2012, doi: 10.5578/kkd.6837.
ISNAD Yıldız, Mustafa et al. “Doğumsal Kardiyak Şantlarla Bağlantılı Pulmoner Arteriyel Hipertansiyonda Tedavi Yaklaşımları: Kardiyoloji Ve Kalp-Damar Cerrahisinde Önemli Bir Yoğun Bakım Hasta Grubu”. Koşuyolu Kalp Dergisi 16/3 (March 2012), 173-176. https://doi.org/10.5578/kkd.6837.
JAMA Yıldız M, Sunar H, Esen AM. Doğumsal Kardiyak Şantlarla Bağlantılı Pulmoner Arteriyel Hipertansiyonda Tedavi Yaklaşımları: Kardiyoloji ve Kalp-Damar Cerrahisinde Önemli Bir Yoğun Bakım Hasta Grubu. Koşuyolu Kalp Dergisi. 2012;16:173–176.
MLA Yıldız, Mustafa et al. “Doğumsal Kardiyak Şantlarla Bağlantılı Pulmoner Arteriyel Hipertansiyonda Tedavi Yaklaşımları: Kardiyoloji Ve Kalp-Damar Cerrahisinde Önemli Bir Yoğun Bakım Hasta Grubu”. Koşuyolu Kalp Dergisi, vol. 16, no. 3, 2012, pp. 173-6, doi:10.5578/kkd.6837.
Vancouver Yıldız M, Sunar H, Esen AM. Doğumsal Kardiyak Şantlarla Bağlantılı Pulmoner Arteriyel Hipertansiyonda Tedavi Yaklaşımları: Kardiyoloji ve Kalp-Damar Cerrahisinde Önemli Bir Yoğun Bakım Hasta Grubu. Koşuyolu Kalp Dergisi. 2012;16(3):173-6.